74 research outputs found
Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury
Mild traumatic brain injury (mTBI) patients may have trauma-induced brain lesions detectable using CT scans. However, most patients will be CT-negative. There is thus a need for an additional tool to detect patients at risk. Single blood biomarkers, such as S100B and GFAP, have been widely studied in mTBI patients, but to date, none seems to perform well enough. In many different diseases, combining several biomarkers into panels has become increasingly interesting for diagnoses and to enhance classification performance. The present study evaluated 13 proteins individually—H-FABP, MMP-1, MMP-3, MMP-9, VCAM, ICAM, SAA, CRP, GSTP, NKDA, PRDX1, DJ-1 and IL-10—for their capacity to differentiate between patients with and without a brain lesion according to CT results. The best performing proteins were then compared and combined with the S100B and GFAP proteins into a CT-scan triage panel. Patients diagnosed with mTBI, with a Glasgow Coma Scale score of 15 and one additional clinical symptom were enrolled at three different European sites. A blood sample was collected at hospital admission, and a CT scan was performed. Patients were divided into two two-centre cohorts and further dichotomised into CT-positive and CT-negative groups for statistical analysis. Single markers and panels were evaluated using Cohort 1. Four proteins—H-FABP, IL-10, S100B and GFAP—showed significantly higher levels in CT-positive patients. The best-performing biomarker was H-FABP, with a specificity of 32% (95% CI 23–40) and sensitivity reaching 100%. The best-performing two-marker panel for Cohort 1, subsequently validated in Cohort 2, was a combination of H-FABP and GFAP, enhancing specificity to 46% (95% CI 36–55). When adding IL-10 to this panel, specificity reached 52% (95% CI 43–61) with 100% sensitivity. These results showed that proteins combined into panels could be used to efficiently classify CT-positive and CT-negative mTBI patients
Immunomodulation of Oxidative Stress during Organ Donation Process: Preliminary Results
The objective was to quantify oxidative stress resulting from ischemia during the donation
process, using malondialdehyde (MDA) measurement, and its modulation by the administration of
melatonin. We designed a triple-blind clinical trial with donors randomized to melatonin or placebo.
We collected donors by donation after brain death (DBD) and controlled donation after circulatory
death (DCD), the latter maintained by normothermic regional perfusion (NRP). Melatonin or placebo
was administered prior to donation or following limitation of therapeutic effort (LTE). Demographic
variables and medical history were collected. We also collected serial measurements of MDA, at
60 and 90 min after melatonin or placebo administration. A total of 53 donors were included (32 from
DBD and 21 from DCD). In the DBD group, 17 donors received melatonin, and 15 placebo. Eight
DCD donors were randomized to melatonin and 13 to placebo. Medical history and cause for LTE
were similar between groups. Although MDA values did not differ in the DBD group, statistical
differences were observed in DCD donors during the 0–60 min interval: −4.296 (−6.752; −2.336)
in the melatonin group and −1.612 (−2.886; −0.7445) in controls. Given the antioxidant effect of
melatonin, its use could reduce the production of oxidative stress in controlled DCD
Protective role of nrf2 in renal disease
Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role in protection against oxidative stress and regulation of the inflammatory response. Consequently, the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseasesThe authors’work has been supported by grants FIS/Fondos FEDER (PI17/00130, PI17/00257,
PI17/01495, PI18/01386, PI19/00815, PI20/00375, PI20/00487 ISCIII-RETIC REDinREN RD016/0009),
Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686
CIFRA2-CM. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
(CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation
(RTI2018-098788-B-100, DTS17/00203, DTS19/00093, RYC-2017-22369, FJC2019-042028), The “PFIS”
and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M
(CD19/00021), and CH-B (CP16/00017). Spanish Ministerio de Ciencia, Innovación y Universidades
(MICIU) grant RTI2018-100695-B-I00, Junta de Andalucía grants P18-RT-4264, 1263735-R and BIO-276,
the FEDER Funding Program from the European Union, and Universidad de Córdoba (to J.M.V.
Effects of blood pressure and tranexamic acid in spontaneous intracerebral haemorrhage: a secondary analysis of a large randomised controlled trial
BACKGROUND: Tranexamic acid reduced haematoma expansion and early death, but did not improve functional outcome in the tranexamic acid for hyperacute spontaneous intracerebral haemorrhage-2 (TICH-2) trial. In a predefined subgroup, there was a statistically significant interaction between prerandomisation baseline systolic blood pressure (SBP) and the effect of tranexamic acid on functional outcome (p=0.019). METHODS: TICH-2 was an international prospective double-blind placebo-controlled randomised trial evaluating intravenous tranexamic acid in patients with acute spontaneous intracerebral haemorrhage (ICH). Prerandomisation baseline SBP was split into predefined ≤170 and >170 mm Hg groups. The primary outcome at day 90 was the modified Rankin Scale (mRS), a measure of dependency, analysed using ordinal logistic regression. Haematoma expansion was defined as an increase in haematoma volume of >33% or >6 mL from baseline to 24 hours. Data are OR or common OR (cOR) with 95% CIs, with significance at p170 mm Hg. Tranexamic acid was associated with a favourable shift in mRS at day 90 in those with baseline SBP≤170 mm Hg (cOR 0.73, 95% CI 0.59 to 0.91, p=0.005), but not in those with baseline SBP>170 mm Hg (cOR 1.05, 95% CI 0.85 to 1.30, p=0.63). In those with baseline SBP≤170 mm Hg, tranexamic acid reduced haematoma expansion (OR 0.62, 95% CI 0.47 to 0.82, p=0.001), but not in those with baseline SBP>170 mm Hg (OR 1.02, 95% CI 0.77 to 1.35, p=0.90). CONCLUSIONS: Tranexamic acid was associated with improved clinical and radiological outcomes in ICH patients with baseline SBP≤170 mm Hg. Further research is needed to establish whether certain subgroups may benefit from tranexamic acid in acute ICH. TRIAL REGISTRATION NUMBER: ISRCTN93732214
Effects of blood pressure and tranexamic acid in spontaneous intracerebral haemorrhage: a secondary analysis of a large randomised controlled trial
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.[Background] Tranexamic acid reduced haematoma expansion and early death, but did not improve functional outcome in the tranexamic acid for hyperacute spontaneous intracerebral haemorrhage-2 (TICH-2) trial. In a predefined subgroup, there was a statistically significant interaction between prerandomisation baseline systolic blood pressure (SBP) and the effect of tranexamic acid on functional outcome (p=0.019).[Methods] TICH-2 was an international prospective double-blind placebo-controlled randomised trial evaluating intravenous tranexamic acid in patients with acute spontaneous intracerebral haemorrhage (ICH). Prerandomisation baseline SBP was split into predefined ≤170 and >170 mm Hg groups. The primary outcome at day 90 was the modified Rankin Scale (mRS), a measure of dependency, analysed using ordinal logistic regression. Haematoma expansion was defined as an increase in haematoma volume of >33% or >6 mL from baseline to 24 hours. Data are OR or common OR (cOR) with 95% CIs, with significance at p170 mm Hg. Tranexamic acid was associated with a favourable shift in mRS at day 90 in those with baseline SBP≤170 mm Hg (cOR 0.73, 95% CI 0.59 to 0.91, p=0.005), but not in those with baseline SBP>170 mm Hg (cOR 1.05, 95% CI 0.85 to 1.30, p=0.63). In those with baseline SBP≤170 mm Hg, tranexamic acid reduced haematoma expansion (OR 0.62, 95% CI 0.47 to 0.82, p=0.001), but not in those with baseline SBP>170 mm Hg (OR 1.02, 95% CI 0.77 to 1.35, p=0.90).[Conclusions] Tranexamic acid was associated with improved clinical and radiological outcomes in ICH patients with baseline SBP≤170 mm Hg. Further research is needed to establish whether certain subgroups may benefit from tranexamic acid in acute ICH.[Trial registration number] ISRCTN93732214.The National Institute of Health Research Health Technology Assessment Programme (11_129_109) and Swiss Heart Foundation.Peer reviewe
Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT
BACKGROUND: Tranexamic acid reduces death due to bleeding after trauma and postpartum haemorrhage. OBJECTIVE: The aim of the study was to assess if tranexamic acid is safe, reduces haematoma expansion and improves outcomes in adults with spontaneous intracerebral haemorrhage (ICH). DESIGN: The TICH-2 (Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage) study was a pragmatic, Phase III, prospective, double-blind, randomised placebo-controlled trial. SETTING: Acute stroke services at 124 hospitals in 12 countries (Denmark, Georgia, Hungary, Ireland, Italy, Malaysia, Poland, Spain, Sweden, Switzerland, Turkey and the UK). PARTICIPANTS: Adult patients (aged ≥ 18 years) with ICH within 8 hours of onset. EXCLUSION CRITERIA: Exclusion criteria were ICH secondary to anticoagulation, thrombolysis, trauma or a known underlying structural abnormality; patients for whom tranexamic acid was thought to be contraindicated; prestroke dependence (i.e. patients with a modified Rankin Scale [mRS] score > 4); life expectancy 4.5 hours after stroke onset. Pragmatic inclusion criteria led to a heterogeneous population of participants, some of whom had very large strokes. Although 12 countries enrolled participants, the majority (82.1%) were from the UK. CONCLUSIONS: Tranexamic acid did not affect a patient's functional status at 90 days after ICH, despite there being significant modest reductions in early death (by 7 days), haematoma expansion and SAEs, which is consistent with an antifibrinolytic effect. Tranexamic acid was safe, with no increase in thromboembolic events. FUTURE WORK: Future work should focus on enrolling and treating patients early after stroke and identify which participants are most likely to benefit from haemostatic therapy. Large randomised trials are needed. TRIAL REGISTRATION: Current Controlled Trials ISRCTN93732214. FUNDING: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 35. See the NIHR Journals Library website for further project information. The project was also funded by the Pragmatic Trials, UK, funding call and the Swiss Heart Foundation in Switzerland
La Proteína S100ß: biomarcador pronóstico tras la lesión cerebral traumática
HIPÓTESIS. La concentración de Pt S100ß en suero, es un marcador con capacidad pronóstica a largo plazo en los pacientes que sufren un TCE grave. OBJETIVOS. 1. Evaluar la capacidad predictora a largo plazo de la Pt S100ß tras el TCE grave.2. Evaluar los niveles de Pt S100ß en el suero de los pacientes con TCE grave.3. Estudiar el curso temporal de las concentraciones de Pt S100ß durante los primeros 4 días de ingreso.Objetivo. Determinar en qué medida la Proteína (Pt) S100ß es apropiada como biomarcador precoz en suero, para la predicción de la recuperación a largo plazo en pacientes que han sufrido un Traumatismo Cráneo-Encefálico (TCE) grave.Métodos. Se estudió una muestra de 98 pacientes con TCE grave según la Glasgow Coma Scale (GCS 8). La concentración de la Pt S100ß fue determinada en cuatro muestras, a la llegada, a las 24, 48 y 72 horas posteriores al TCE (días 0, 1, 2, 3). La recuperación fue evaluada a los 12 meses utilizando la Glasgow Outcome Scale (GOS). - Resultados. Los resultados mostraron una correlación negativa significativa entre el GOS alcanzado a los 12 meses y la concentración de Pt S100ß en los días 1-3, pero no en el Día 0 (Día 0, p =0,09; Día 1. p = 0,004: Día 2, p < 0,0001 ; Día 3, p < 0,0001). La buena recuperación (GOS = 4-5) Vs Mala recuperación (GOS =1-3) difieren significativamente en los Días 2 y 3 ( p < 0,05). El análisis de la regresión logística muestra que solamente la muestra recogida a las 72 horas post-TCE predice la recuperación: Exitus ( p < 0,0001); mala recuperación ( p = 0.0009). En la muestra del día 3 la curva ROC demuestra la más alta clasificación en la precisión y difiere significativamente del Día 0 ( p = 0,02). Los valores de punto de corte pronóstico para la Pt S100ß, a las |Premio Extraordinario de Doctorado U
Parada circulatoria cerebral detectada por la insonación de arterias extracraneales
Peer reviewe
Predicting the risk of death or vasospasm in a patient with a subarachnoid hemorrhage
La invención describe un método para predecir o pronosticar el riesgo de muerte o vasoespasmo en un paciente con hemorragia subaracnoidea que comprende los siguientes pasos: realizar una evaluación clínica del paciente según las escalas Hunt- Hess y WFNS
- …